文献速递糖尿病

SLC2A2附近常见遗传变异与格列美脲血糖反应:GRADE试验药物基因组学发现

Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial.
PubMed 文献 · Diabetes Care · 2026-11-05

在GRADE随机对照试验中开展全基因组关联研究,分析二甲双胍基础上加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀后血糖反应。SLC2A2(编码GLUT2)的rs2129019在非裔人群中富集,每携带一个A等位基因,格列美脲治疗失败风险增加38%(P=1.55×10-8)。携带者β细胞功能受损、对磺脲类急性降糖反应减弱,提示该变异可调节磺脲类疗效。

要点

  • SLC2A2 rs2129019 A等位基因与非裔人群格列美脲代谢失败风险增加38%相关。
  • 携带者OGTT中C肽指数更低,提示β细胞功能受损。
  • 该变异可能帮助识别磺脲类低反应者,指导个体化选药。

核心结论

  • SLC2A2遗传变异可调节磺脲类药物的血糖反应,rs2129019 A等位基因携带者格列美脲治疗失败风险更高。

研究设计与样本

  • 在GRADE随机对照试验中开展药物基因组学全基因组关联研究,分析二甲双胍基础上加用四种降糖药的血糖反应。
  • 在独立队列中复制,对SLC2A2附近变异精细定位,并用OGTT和急性格列吡嗪刺激评估生理影响。
  • 在slc2a2突变斑马鱼模型中验证格列美脲的降糖反应。

主要发现

  • rs2129019在非洲/非裔美国人参与者中富集,每A等位基因使格列美脲代谢失败风险增加38%(P=1.55×10-8)。
  • 携带者OGTT期间C肽指数更低,提示β细胞功能受损。
  • 携带者对急性磺脲类刺激的降糖反应减弱。
  • 斑马鱼slc2a2破坏减弱格列美脲降糖效果。

关键数值与推荐

  • 主要代谢失败定义为HbA1c≥7%,次要定义为HbA1c>7.5%。
  • rs2129019每A等位基因风险比对应38%增加,P=1.55×10-8。

临床怎么用

  • SLC2A2变异信息可能辅助识别磺脲类低反应者,考虑替代降糖方案。
  • 目前证据尚不支持常规基因检测指导选药,需进一步研究。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Optimizing second-line therapy for type 2 diabetes remains challenging because of interindividual variability in response. Current treatment selection does not consider personal genetic profiles. To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin. RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE), we performed a GWAS for the time to reach primary (glycated hemoglobin [HbA1c] ≥7%) and secondary (HbA1c >7.5%) metabolic failure. We conducted replication in independent cohorts, performed fine mapping of the top variants near SLC2A2, evaluated them for physiologic impact using oral glucose tolerance testing (OGTT) and response to acute glipizide challenge, and characterized glycemic response to glimepiride in an slc2a2-mutated zebrafish model. RESULTS: rs2129019 in SLC2A2 encoding GLUT2 was enriched in African/African American participants and conferred a 38% increased risk of metabolic failure per A allele on glimepiride (P = 1.55 × 10-8). Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuated the glucose-lowering effect of glimepiride. CONCLUSIONS: Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Li JH, Szczerbinski L, Tripputi M, et al. Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial. Diabetes Care. 2026. PMID: 42986362. doi:10.2337/dc26-1633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。